Turn Therapeutics Inc. Financial Summary

Quick Answer

Turn Therapeutics Inc. reported Net Income of -$3.19 million for fiscal year 2025.

Turn Therapeutics Inc. — Key Financials by Year

Metric 2025 2024 2023
Net Income -$3.19M
-80.6%
-$1.77M
Diluted EPS -$0.12
-71.4%
-$0.07
Total Assets $12.16M
+493.6%
$2.05M
Stockholders Equity $4.69M
+2741.4%
-$177.4K
-306.9%
$85.8K
R&D Expense $265.6K
+8.0%
$246.0K
Operating Income -$5.86M
-226.0%
-$1.80M

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Net Income September 30, 2025 -$1.90M -185.7% -185.7%
Diluted EPS September 30, 2025 -$0.07 -133.3% -133.3%
Total Assets September 30, 2025 $4.30M +109.8%
Stockholders Equity September 30, 2025 $504.0K +221.7% +384.1%
R&D Expense September 30, 2025 $158.7K +3.5% +3.5%
Operating Income September 30, 2025 -$1.91M -184.3% -184.3%
  • Turn Therapeutics Inc. reported Net Income of -$3.19 million for fiscal year 2025.
  • Turn Therapeutics Inc. showed a decrease of -80.6% in Net Income compared to the prior fiscal year.
  • Turn Therapeutics Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
  • Turn Therapeutics Inc. showed a decrease of -71.4% in Diluted EPS compared to the prior fiscal year.
  • Turn Therapeutics Inc. reported Total Assets of $12.16 million for fiscal year 2025.
  • Turn Therapeutics Inc. showed an increase of +493.6% in Total Assets compared to the prior fiscal year.
  • Turn Therapeutics Inc. reported Stockholders Equity of $4.69 million for fiscal year 2025.
  • Turn Therapeutics Inc. showed an increase of +2741.4% in Stockholders Equity compared to the prior fiscal year.
  • Turn Therapeutics Inc. reported R&D Expense of $265.6 thousand for fiscal year 2025.
  • Turn Therapeutics Inc. showed an increase of +8.0% in R&D Expense compared to the prior fiscal year.
  • Turn Therapeutics Inc. reported Operating Income of -$5.86 million for fiscal year 2025.
  • Turn Therapeutics Inc. showed a decrease of -226.0% in Operating Income compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment